Novel Sorrento CAR-T technology a potential “game-changer

Company envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.

Sorrento Therapeutics' Dr Henry Ji, Chairman & CEO will share recent Sorrento developments and company information in a panel discussion of “R&D Trends: What's Changed in the Pharma Pipeline?” (Saturday, 6 January 3:50 - 4:20 pm PST) in the upcoming “East/West CEO” conference at the Four Seasons Hotel in San Francisco, CA. During the panel discussion, Dr Ji will present the development of a proprietary non-viral chimeric antigen receptor (CAR)-T technology that may fundamentally alter the way that CAR constructs can be integrated into T cells.

Novel Sorrento CAR-T technology a potential “game-changer

This novel Sorrento CAR-T technology has already been utilized preclinically to generate CD38 CAR-T and CD19 CAR-T cells. These CAR-T cells have been evaluated and compared against CAR-T cells generated using current retrovirus transduction methods. Data suggest that the non-virally generated CAR-T cells performed similarly to retrovirally-transduced CAR-T cells with regards to CAR expression, cytokine production, and cytotoxicity against target-expressing tumor cells.

This innovative non-viral CAR-T technology may offer several potential benefits compared with existing virus-based technology using CAR gene-encoding lentivirus, retrovirus or adeno-associated virus (AAV) to introduce CAR constructs into healthy donor (allogeneic) or cancer patient (autologous) T cells. These potential advantages of Sorrento’s non-viral CAR-T technology include

  • site-specific integration of CAR constructs into a pre-selected locus in the T cell genome
  • streamlined method for CAR construct production without need for laborious and time-consuming CAR-encoding virus production, release and validation processes, resulting in a shorter development timeline for IND preparation
  • potential elimination of added burden to patients of lengthy monitoring period for the absence of replication competent virus (i.e., FDA currently requires a 15-year follow-up for patients treated with the virally transduced CAR-T cells)
  • applicability to both autologous and allogeneic CAR-T therapies
  • shortened development timelines to bring new CAR-T therapies faster to patients in need.
  • Sorrento is planning on applying its innovative non-viral CAR-T technology to CAR-T programs for multiple hematological and solid tumor indications, including but not limited to: multiple myeloma, lymphoma, liver cancer, sarcoma, pancreatic cancer and glioma. Utilizing the vast portfolio of target-specific, fully human monoclonal antibodies discovered from its proprietary G-MAB library, Sorrento envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.

    “Building on our preclinical and clinical experience in CAR-T cell manufacturing with our “state-of-the-art” cGMP facilities, and looking at the next frontier, we are excited to share this robust development of non-viral CAR-T technology for both autologous and allogeneic CAR-T therapies. This new “game-changer” technology may translate into faster development timelines, more cost-effective cGMP manufacturing and possible removal of the regulatory requirement to follow patients for 15 years post treatment,” stated Dr. Henry Ji. “We also have obtained preclinical data suggesting that cord blood T cells are a potentially rich and valuable “off-the-shelf” T cell source, enabling allogeneic CAR-T therapy. Working with our strategic partner, Celularity, Inc.1, Sorrento intends to develop multiple, potentially paradigm-shifting allogeneic CAR-T programs for hematological and solid tumor indications with high unmet medical need.”

    Read More



    Other news in “Research & Development”

    Manufacturing collaboration to advance PMD-026 toward IND

    Manufacturing collaboration to advance PMD-026 toward IND 

    18 Apr 2018
    Omega-3s from fish oil supplements no better than placebo for dry eye

    Omega-3s from fish oil supplements no better than placebo for dry eye 

    15 Apr 2018
    Hope on the horizon for hair loss sufferers

    Hope on the horizon for hair loss sufferers 

    13 Mar 2018